The On Demand Agenda

  • 150+sessions
  • 300+speakers
  • 4days of content
  • 8 interest areas

Day 1 (EST)


Welcome from eyeforpharma


A relentless pursuit to learn from patients

  • How to recognize the value of “human” contributions to health care from patients, employees and advocacy organizations
  • How using the SECI* Model knowledge creation process can lead to continuous innovation
  • As stewards of data obtained through multiple touchpoints, how can the pharmaceutical industry combine data with science as we strive towards the common goal of developing lifesaving treatments and solutions for patients?

Ivan Cheung Chairman Eisai Inc.


Will you meet your patients' post-pandemic expectations

  • What are the new patient expectations, and which changed healthcare habits will be sticky?
  • Consider the role of digital health in a strategy to address those new patient expectations.
  • How deep patient data supports actionable decision-making for evidence payers want for outcomes-based contracts.

Tom Rhoads CEO Spencer Health


How Sanofi Pasteur is reengineering clinical trials together with health care systems

  • How we can reinvent ourselves working with regulators and healthcare systems
  • How sophisticated analytic is finding new correlations & understanding through large volume of structured data
  • Why interoperability and data harmonization can unlock a new future for healthcare and the industry

David Loew EVP & Head Sanofi Pasteur


Health in a connected world

  • With mobile consumption surpassing traditional channels, the way people connect with each other and with businesses has changed. Through resources like Health Support groups, the Preventative Health tool and Blood Donations tool, communities have come together on Facebook to start critical conversations around health.
  • This presentation will walk through the ways people are turning to mobile for their health information and provide recommendations for how Pharma companies can drive impact throughout the full funnel patient journey. Facebook will share how it’s investing in public health, along with creative examples from Health brands getting it right on the platform.

Danielle Salowski Industry Manager, Health Facebook


Leadership through crisis: Adapting and innovating to better serve our stakeholders

  • Show examples of how adaptability and innovation can help an organization move through a crisis period.
  • Illustrate how new ways of working and enhanced capabilities will make Bayer a better employer and stronger at delivering to customers and patients post-crisis.
  • Demonstrate that a strong culture is the foundation for all that we must do during tough times.

Sebastian Guth President, Americas Region Bayer


Patient Centricity: The Power of Co-Creation

  • "How ‘patient centricity’ is not a destination or even a goal- it’s a day-by-day process
  • How to hold yourself and your teams accountable through tangible metrics and prove you are really ‘patient-centric’"

Laurie Meyers Head of CMG Patient Engagement Genentech


PANEL: Your leadership model for customer centricity in the digital era

  • Define the role of digitally-driven sales teams, form the leadership team and set your commercial digital transformation strategy
  • Cultivate a data delivery system which empowers the ‘analytical sales rep of the future’ with well timed, well placed customer insights (medical, access, patient engagement)
  • Avoid and overcome common leadership pitfalls in the pursuit for digital domination

Soma Gupta Chief Commercial Officer G1 Therapeutics

Igor Rudychev Head, US Data & Innovations, Oncology Business Unit AstraZeneca

John Young IT Sales & Marketing Enablement Technologies Leader Mallinckrodt Pharmaceuticals

Veronica Chase VP Marketing Eli Lilly


Staying engaged: Applying next-gen patient storytelling techniques to the COVID challeng

  • Learn how to engage patients during COVID-19 with virtual and digital experiences
  • See examples of live virtual patient engagement, virtual content co-creation, and mentor programs that help patients cope in stressful times
  • Discover the power of agile methods to produce timely, authentic, and relevant user-generated content
  • See why brands are shifting dollars to social to tell authentic stories where patients engage

Jon Irvine Creative director Snow Companies

Phil Storer SVP Snow Companies

Blake Shewey EVP, Client Service Snow Companies


You can do it too: going agile in the FDA environment

  • Regulatory requirements mean that bold changes in direction can be hard, yet locking-in strategy is the antithesis of agile marketing.
  • Adopt a test and learn approach throughout to stay close to the end user
  • Master agility to justify and qualify your approach as you streamline and motivate teams to deliver faster

Erin Russell General Manager and Associate Vice President Spotlyte


Real-world and longitudinal analytics to uncover precise patient and HCP insights

  • Learn how Clarify Health seamlessly integrates disparate healthcare data onto one user-friendly, analytics platform
  • Discover our differentiated Life Sciences offerings which are helping leading pharma launch and accelerate product growth
  • Examine case studies where traditional (i.e., clinical, claims) and non-traditional (i.e., socio-behavioral) data are used to inform pharma commercial strategy

Anna Xie Director, Life Sciences Clarify Health


We need to talk about... Health literacy

  • Make it easier for patients to deal with the wave of misinformation in the era of ‘post-truth’
  • Understand the best practices for communicating HCP and Regulatory data to patients
  • How we can work with patient advocacy groups, education forums and HCPs to communicate directly to patients and build higher levels of literacy and understanding

Laurie Myers Global Health Literacy Director Merck

Lori Hall Director, Global Health Literacy Eli Lilly

Esther Schorr Co-founder and COO Patient Power

John Linnell COPD Patient advocate


A Reuters News lead interview with Peter Bach: The impact of COVID-19 on drug pricing

Axel Thelfall, Editor-AT-Large of Reuters interviews Peter Bach, Director, Centre for Health Policy and Outcomes at the Memorial Sloan Ketterling Cancer Center, on all things pricing and whether he thinks COVID-19 will change anything for the better. They have a lively discussion around opportunism, PR, corporate decision making, and collaboration within the pharma industry around drug pricing during and following the crisis.

*Please note: This interview is conducted by Reuters editorial, which operates independently from the Reuters commercial operations. Reuters journalists have the sole right to determine who they interview and the questions they ask, with no regard to sponsorship and in keeping with the Trust Principles of integrity, independence and freedown from bias.

Peter Bach Director, Center for Health Policy and Outcomes Memorial Sloan Kettering Cancer Center

Axel Threlfall Editor-at-Large Reuters


An interview with Rob Dickerson: Leadership and the virtual field force

Rob Dickerson Former Head of Commercial Excellence Novartis

Paul Simms Chairman eyeforpharma


Advancements in digital technology: Harnessing innovation to meet today's marketing challenges

  • Learn how to use data technology to generate actionable insights and personalize campaigns
  • Transform your marketing campaigns with digital innovations such as AI
  • Solve basic, practical business problems with advanced technology

Christina Kim EVP of Data Analytics at Omnicom Health Group BioPharm Communications


We’re all in this together: Holding and sharing internal customer data

  • See what effective data ownership and management looks like when tailoring an effective strategy for your company
  • Integrate data ownership with analytics strategy and execute across functions to deliver intelligent engagements
  • Gain practical solutions to communicate collaboratively and break down internal barriers

Renaud Sermondade VP, Global Head of Insights & Analytics Sanofi


A Reuters News lead interview with George Yancopoulos: Key update on COVID-19 treatment progress

Axel Threlfall, Editor-At-Large of Reuters interviews George Yancopoulos, Co-Founder and Chief Scientific Officer at Regeneron. They discuss the work Regeneron is doing on two potential COVID-19 treatments, the first being a repurposing of its Arthritis drug, Kevzara, and the second, an antibody cocktail.

*Please note: This interview is conducted by Reuters editorial, which operates independently from the Reuters commercial operations. Reuters journalists have the sole right to determine who they interview and the questions they ask, with no regard to sponsorship and in keeping with the Trust Principles of integrity, independence and freedown from bias.

Axel Threlfall Editor-at-Large Reuters

George Yancopoulos Co-Founder, President and Chief Scientific Officer Regeneron


The future of medical: Drivers of value throughout lifecycle strategy

  • Defining our identity now and in the future
  • Meet the surging resource demand from customers, without compromising scientific integrity
  • What organizational design and capabilities do we need to meet these expectations?

Michael Norton VP, Head US Medical Affairs AbbVie

Harmony Garges Chief Medical Officer ViiV Healthcare

Jasmina Mioc Director, Medical Affairs Boehringer-Ingelheim (Canada)

Sebastian Sorsaburu VP Medical Affairs Amgen

Robert Consalvo Director of Strategic Commercial Engagement H1 Insights


Financing the future: Precision financing innovations to enable patient access to durable, curative therapies

  • Understand innovative reimbursement models that address the financial challenges of these new therapies
  • Hear the implementation hurdles encountered by initial pilots
  • Learn how to tailor these approaches to product archetypes and payer segments

Mark Trusheim Strategic Director MIT NEWDIGS


Virtual Research: What it is and what it's doing in the real-world setting

  • #VirtualResearch is the latest trending topic in clinical research, why consensus on terminology is required
  • Aligning virtual research approaches through a classification scheme understanding their differences
  • Examples of how the real-world setting has become the testing grounds for virtual approaches

David Thompson SVP, Real World and Late Phase Syneos Health


Disrupting the healthcare model: The shift to patient control of drug access and treatment

  • Hear how GoodRx has changed access to medicines for over 20 million consumers via a free-to-use website and mobile app that tracks prescription drug prices and offers drug coupons across the US
  • Discover why this has led the company to launch GoodRx Care to provide online medical service to provide consultation, treatment, prescriptions and lab tests from doctors
  • Learn how the service is built to improve access, adherence, and affordability of medical care for all Americans and put control of healthcare firmly in the hands of patients

Vanessa Segura Partnership Manager GoodRx


Health start-up challenge: You decide

  • 5 of the most innovative start-ups in healthcare and pharma compete for your vote

Joe Baffone CEO & Co Founder Annexus Health

Kevin Bambury Co-Founder/Chief Commercial Officer ONCOassist

Jordan Mills CEO MirrorMe3D

Jeff Valk CEO Admetsys Corporation

Patrick Anquetil CEO Portal Instruments

Day 2 (EST)


Seen and heard? Elevate your brand above the din of digital saturation

  • Ways to differentiate your brand in world of information overload
  • Maximize multiple touchpoints to supercharge your data gathering and better understand your customer
  • Leverage insights effectively to tailor your communications, better resonate with your audience and translate digital impressions into actual sales
  • Explore how you can incorporate real-world moments into your marketing strategy that enhance the digital experience of consumers

Johanna Willer Senior Advisor, Next Generation Customer Engagement Eli Lilly


The moment of next: How native digital experiences drive physician engagement

  • Learn how cognitive load and contextual relevance impact receptivity to marketing messages – and how to use them to your advantage
  • Gain insight into how native strategies go beyond the click to deliver lift in downstream interaction and engagement
  • Discover how AstraZeneca used native traffic drivers to increase on-site conversion and campaign performance

Amy Turnquist Executive VP, Digital Solutions eHealthcare Solutions (EHS)

Gus Strominger Senior Marketing Manager, Digital & Media Strategy AstraZeneca

Tashauna Brown Chief Operating Officer TrendMD


Time to get personal: Strengthen customer relationships with Personal Intelligence Marketing (PIM)

  • Case study: Discover how GSK delivers daily personalized and tailored messages to customers using the first orchestrated trigger program, the award-winning Personal Intelligence Marketing (PIM) Trigger Program
  • Progress HCPs through a complete user journey that avoids repetition of consumed messages and achieves sophisticated segmentation
  • Make the best use of your data analytics to improve relationship-building, strengthen lag metrics and boost satisfaction among customers

Jay Sabbah Senior Director, SHINGRIX Marketing (US Brand Lead) GlaxoSmithKline


Five surprising relationship truths after “Tiger King”

  • Things have changed in the era of COVID-19. Some things won’t change back.
  • A look at our real-time research and perspective on the months ahead for healthcare.

Marcy Q. Samet Global Chief Marketing Officer MRM

Rob Rothschild SVP, Global Strategy, Health Practice Lead MRM


Revolutionize your customer journey through AI

  • Learn how Bayer is using AI to transform how customers are engaged, building more effective relationships
  • Get the right data – find the right partners who will help you gather and hold data better
  • Develop analytics strategies that enable you to be ambitious while staying compliant
  • Set execution strategies that are easy for reps to take on and carry out well

Helena Yin Koeppl VP, Global Head of Data Science & Advanced Analytics Bayer


An interview with Richie Etwaru: Are privacy and consent vital in a data collaboration emergency?

Richie Etwaru CEO

Paul Simms Chairman eyeforpharma


Systems thinking is your key to improving quality outcomes for providers and patient

  • Medical must level-up healthcare system knowledge to keep up with stakeholder evolution
  • How patients flow within healthcare systems and the impact on clinical pathway
  • The future architecture of care: engage with complexity to improve quality outcomes

Eddie Power VP, North America Medical Affairs, Hospital Business Pfizer


Rebranding RWE: How to change how we talk about RWE and who accepts it

  • Learn which customers are ready to accept RWE now—and why
  • Understand why customers are skeptical and how to address their concerns
  • Diagnose gaps in your approach to demonstrating value with RWE

Madhavi Kasinadhuni Managing Director, Life Sciences Research Advisory Board


Implementation Science: Bridging the gap between research and practice

  • What is Implementation Science?
  • Why should Pharma care about IS?
  • How is ViiV applying IS to its novel pipeline?

Maggie Czarnogorski Head of Implementation Science ViiV


Your external stakeholders have changed: Has your strategy kept pace?

  • Medical’s stakeholders now include social media influencers, patient groups and digitally driven HCPs
  • Publishers are in search of innovative digital ways for providers, payors, and patients to consume scientific/medical information
  • Case Study: How we can collaborate cross-industry to create a new trusted digital resource for HCPs

Patrick Reilly CEO PhactMI


Prioritizing attributes for virtual medical affairs engagements: An evaluation of the current environment

Pat Baffuto Vice President, Client Services, Hybrid Healthcare Communications Hybrid


Advancing medical's value proposition for HCPs with digital innovation (mobile app for depression)

  • A panel of experts representing patients, providers, health care systems and the pharmaceutical industry will share perspectives on digital advancements in mental health from research collaboration to practice. The opportunity to continuously monitor patients, whether passively or actively, can redefine the Mental Health field and how clinicians and patients currently engage during treatment. Technology is playing a central role in supporting the development of digitally enabled care pathways, particularly in depression, facilitating collaboration, shared decision making and integration across multiple care providers and settings; improving communication between patients and clinicians; increasing efficiency and empowering patients to manage their mental health and wellbeing more effectively. New science, trends and considerations for optimizing technology to improve the delivery of mental health care will be discussed and examples of multi stakeholder collaborations shared.

Jill Erickson Sr. Director, Medical External Affairs US Medical Integration Lead Takeda

Maggie McCue Clinical Science Director, US Medical Takeda

Ben Fehnert Co-founder Ctrl Group

Chris Blair Director Advocate Research Institute


It's time for a digital reset, Pharma. Building the customer experience framework of the future

  • What should the evolution of your digital strategy look like through COVID-19 and beyond?
  • Short and long term strategic approaches to differentiate and “reset” given the new normal.

Corey Mogk AVP, Omnipresence, Product Success Indegene

Michelle Keefe President Commercial Solutions Syneos Health

Desmond Creary Health Business Leader of the Americas Microsoft


An interview with Kabir Nath: Leadership through and beyond today's pandemic

Kabir Nath President and CEO North America Otsuka

Paul Simms Chairman eyeforpharma


Digital futures to digital realities: Engagement in today's new normal

  • Review how COVID-19 has altered healthcare engagement and forced us to pivot and challenge our digital strategies
  • Review how Salesforce customers are pivoting to accelerate digital engagement strategies and opening the doors to new, novel approaches from virtual trials to digital therapy launches and widespread adoption of telehealth
  • Discuss potential long-term implications for the healthcare and pharma industries

Glenn Wada Senior Vice President Salesforce


An interview with Jayne Gershkowitz: Build a corporate strategy through greater patient empowerment

Jayne Gershkowitz Chief Patient Advocate Amicus

Paul Simms Chairman eyeforpharma


Harnessing the voice of the customer: How to build an award-certified patient engagement program

Scott Killingsworth Director, Customer Service Solutions J.D. Power

Robert Selvaggi Director, Contact Center Operations Amplity Health

Gail Markiewicz Senior Manager, Patient Experience Sunovion

Marc Wiedenmann Associate Director, Patient Experience Sunovion


An interview with Simon Davies: A perspective on pharma innovation from teen cancer groups

Simon Davies CEO Teen Cancer America

Paul Simms Chairman eyeforpharma


IDNs: Where we want to work to create value

  • How Fairview is creating a forum for partnership via the Pharma Symposium
  • Explore the key successes and challenges faced in pharma-provider co-creation
  • Discuss what the future direction of the health eco-system is, and what pharma-provider partnerships will look like

Jacob Jolly Director, Specialty Pharmacy Strategy and Market Access Vanderbilt University Medical Center

Melissa Skelton Duke, PharmD, MS, BCPS, FAPhA Executive Director, Population Health Pharmacy Solutions Banner Health

Timothy Paine VP, Pharma Strategy & Relations Fairview Specialty Pharmacy


A moonshot trial with payers, providers and regulators

  • Pharma companies often cite the requirements of payers, providers and regulators as the reason for rigidity in trial design. Does that excuse still wash?
  • Examine what a co-created public-private partnership could generate in terms of trial design
  • Examine what’s required to build out a trial infrastructure/regulatory framework in a region that would enable digital trials to be done at scale

Jacob LaPorte Co-founder, BIOME Novartis


Clinical research as an open platform

  • The future of clinical trials is defined by information – how we collect it, process it, and ultimately apply insights to produce better & safer therapeutics that reach our patients faster
  • The shift to niched indications with smaller patient cohorts will require greater vendor specialization
  • This distributed model will demand holistic trial data standards, which will ease pressures on CROs, reduce trial costs & timelines, and improve data fidelity
  • Learn about how Lokavant is working to enable this future by building an operational platform for clinical trial data management and anticipatory analytics

Rohit Nambisan President Lokavant


Incorporate the patient voice in drug development – it’s easy when you know how

  • How TransCelerate tools have been developed to enable and normalize patient involvement – and can be embedded into your processes, including protocol design
  • Examine how 21st Century Cures, PFDD, FDA consultations and other sources have fed into a reliable design that ultimately enables your regulatory filings to shine
  • Why templating patient involvement can mobilize a wave of new engagement across your organization

Mary Elmer Executive Director Merck


Fireside chat: Why gene therapies have broken scientific boundaries and will now transcend commercial boundaries

  • How and why gene therapies have broken scientific boundaries
  • How the science of gene therapy has redefined what is possible for medicines
  • How value models are being innovated to create access

Jeff Marrazzo CEO Spark Therapeutics

Day 3 (EST)


How and why AstraZeneca enlisted artificial intelligence for sales rep coaching

  • Learn how AstraZeneca’s AI strategy was developed to deliver value to their customers
  • Explore the capabilities of an AI-driven workforce by commercial application, tried and tested
  • Understand AstraZeneca’s need for enhanced training, coaching and progress monitoring and the process behind adopting AI to meet this
  • Hear how commercial leaders at AstraZeneca are measuring workforce effectiveness and productivity via AI

Kevin Murray Associate Director, Commercial Leadership Excellence AstraZeneca

Spencer Holt PhD Head, Commercial Learning Innovation Centre AstraZeneca


Case study: Optimizing commercial execution in a dynamic, complex market

  • From precise planning to flawless execution with effective analytics
  • How IronShore launched their first medicine ensuring data-driven decisions
  • Facilitate true collaboration across commercial functions

Peter Lammers IronShore, Chief Commercial Officer Ironshore Pharmaceuticals

Amin Torabkhani IronShore, Director of Sales Operations and Analytics Ironshore Pharmaceuticals

Peter Harbin SVP Commercial Strategy and Industry Solutions Verix


Upgrading commercial targeting for the age of IDNs: How next level data and analytics can help your sales force work smarter and better engage organized customers

  • The increasing importance of health systems and IDNs has made the task of targeting and prioritizing accounts more complex, yet also more critical. Pharma needs to evolve its approach to identifying and engaging customers. We'll discuss how pharma can:
    Weave together siloed data streams to characterize, segment, and prioritize accounts for engagement
  • Leverage new and emerging data sources and visualization tools, along with traditional metrics and inputs in order to minimize the time and leg work reps need to invest in order to reach the ideal stakeholders

Ryan Rumantir Associate Lead, Client Engagement Decision Resources Group


Fireside Chat: The analytical rep of the future

  • As the face of pharma, the modern salesforce must embody digitally-enhanced customer value; learn how Novartis are leading the charge in their commercial functions
  • Develop a new commercial operational model which enables field units to connect to increasingly collaborative access, marketing, medical and patient functions
  • Patient value is the currency of tomorrow’s industry: Train your salesforce to deliver a seamless hybrid between face-to-face interaction and backend process

Bharti Rai VP Commercial Acceleration/ Effectiveness Novartis


Invest time, money and manpower today to grow the commercial field force of the future

  • Smart commercial teams are those who are prepared, even ahead of change: Define the “top performer” of tomorrow and benchmark your commercial functions ahead of the curve
  • Hear about the existing commercial models that have proven to deliver an analytical and customer-first approach
  • Understand the process behind L&D programs and the requirements for creating the agile account managers at the forefront of pharma’s future

Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals

Jenn Muszik Head, US Commercial Learning Biogen


Rebranding RWE: How to change how we talk about RWE and who accepts it

  • Learn which customers are ready to accept RWE now—and why
  • Understand why customers are skeptical and how to address their concerns
  • Diagnose gaps in your approach to demonstrating value with RWE

Madhavi Kasinadhuni Managing Director, Life Sciences Research Advisory Board


Valuing innovation: From pandemic to me-too

  • Consider if there are differences in how we incentivize innovation depending on what problem we're trying to solve
  • Explore how we view incentives in a pandemic situation
  • Discuss whether the pre- and post- COVID19 worlds look different - will we go back to value assessment the way we did in the past?
  • Determine how our practices are likely to change beyond recognition

Chris Leibman SVP, Value and Access Biogen

Robert W. Dubois CSO & EVP National Pharmaceutical Council

Sarah Emond EVP and COO ICER


Access and affordability is now a cross-functional priority

  • As the industry shifts towards value, access is everybody’s business
  • Hear Commercial, Patients and Medical leadership break down why the future of your function is driven by Access
  • As we converge around access and affordability, this is how we work cross-functionally to achieve our goals

Sheila Frame VP Commercial: Marketing, Market Access and Patient Services Sandoz

Daniel Staud AVP Global Market Access Merck

Craig Granowitz, MD, PhD SVP, Chief Medical Officer Amarin Corporation

Sue O’Leary VP, Prime Access, Global Market Access & HEOR Prime Access

Hazel Moran Head, Strategy and Engagement, Government and Public Affairs EMD Serono


An interview with Paul Rowe: The future of Medical

Paul Rowe, MD VP, Head of Global Medical, Immunology Sanofi Genzyme

Paul Simms Chairman eyeforpharma


Adding the Medical Affairs voice for leveraging RWE and big data to transform tools for payor conversations

  • Collaborating with HEOR, Market Access, and Field Medical to determine payor needs, create a strategy, and execute
  • How Novo Nordisk is using RWE to help employers uncover employee health needs
  • Provide an example of how Medical Affairs can reestablish pharma’s credibility with customers by supporting access to industry’s big data

Gabriel Smolarz US Medical Director - Obesity Novo Nordisk


Complete your picture of patients: A hybrid study proof of concept

  • Integrate multiple clinical and real-world data sets including EDC, EMR, devices, eCOA and lab data
  • Use tokenization to link patients across data sets without having to transfer or expose PHI
  • Review a proof-of-concept study exercising new framework, from data collection through statistical analysis and TLF generation

Craig Parker, MD, MS VP, Scientific Data Technology Parexel


Fireside chat: How patient groups can be the bridge to precompetitive collaboration with RWE

  • IBD PLEXUS Case Study: How Crohn’s & Colitis Foundation united patients and pharma
  • Turn competitors into collaborators: how to build emergent coalitions

Caren Heller CSO Crohns Colitis foundation


An interview with Patrice Baudry: Reorganizing LEO for growth without losing core principles

Patrice Baudry EVP, Global Marketing and Market Access LEO Pharma

Paul Simms Chairman eyeforpharma


What robots and rare diseases have in common: Artificial Intelligence

  • How to use AI to help IDNs identify patients living with an unmet need
  • Engage IDNs with RWE to prove unmet patient need
  • Pilot case study: How to utilize AI to connect patients to care

Sonal Bhatia, MD VP, North America Medical Lead, Rare Disease Pfizer


Personalization: The digital transformation of Market Access marketing

  • Achieve personalized access and enhanced availability with multichannel delivery (via a sophisticated Market Access ecosystem)
  • Revolutionize your Market Access marketing strategy with social as an HCP engagement channel
  • Execute on a sophisticated delivery of personalized messaging with the latest emerging AR (Augmented Reality) technology

Jon Bambalas Vice President of Business Development for Engagement Solutions Precision Xtract

Marty Samples Vice President of Product Innovation and Marketing for Personalized Access Solutions and Consulting Precision Xtract


Reinvent customer engagement from the outside-in

  • Discover how pioneering customer engagement models have propelled other industries to new levels of success – and which apply to you
  • Take from tech giants – identify web 2.0 models that can upgrade your communications without risking non-compliance
  • A guide to skills and processes that will be essential for tomorrow’s pharma leaders

Haider Alleg Global Head of Digital Excellence Ferring

Todd Neuville Worldwide Business Development Leader for Life Sciences Amazon Web Services


Harness the combined power of commercial as sales, marketing and data evolve

  • Break down commercial silos as sales, marketing and data evolve to construct a unified view of the customer
  • Utilize cross-functional capabilities to build a sophisticated and authentic comprehension of patient value
  • Examine the shifting role of commercial ops as a support versus partnership function to the wider business, how leaders are achieving this and why it is important
  • Explore the common pitfalls related to data and insight exchange at the sales rep and field force level; and how leaders are overcoming these to provide optimal insights to their customers

Mundo Vega Associate Director - Global Commercial Operations, Business Analytics AbbVie

Kishan Kumar Director, Commercial Strategy & Operations, Oncology Novartis

Spencer Holt PhD Head, Commercial Learning Innovation Centre AstraZeneca

Rj Lasek VP Commercial Operations Takeda


An interview with Jessica Federer: How pharma can find wins through start-up collaboration post COVID-19

Jessica Federer Former Chief Digital Officer Bayer

Paul Simms Chairman eyeforpharma


Where is tech innovation bringing real value in healthcare – and how are pharma companies keeping pace?

  • In which areas are new tech advances driving innovation in healthcare? How do pharma companies need to adapt to stay relevant?
  • Discover how strong data analysis is now seen as a core competency and where it can reveal unseen insights to add significant business value
  • Learn how integrating AI, blockchain, VR/AR and other emerging technologies is accelerating productivity and efficiencies across the industry
  • Understand how working with startups can accelerate digital innovation and foster new ways of working for better overall outcomes

Natalija Jovanovic Chief Digital Officer Sanofi Pasteur

Nathan Yorgey Director of Digital Innovation Pfizer

Greg Silvesti Head of Digital Health & Innovation AbbVie

Ahmed Albaiti Founder, CEO Medullan

Day 4 (EST)


Trials during the pandemic: Forecasts for both sides of the curve

  • Discuss the state of trials today
  • Review priorities to ensure trial continuity during the pandemic
  • Explore what is needed for innovation to sustain and outlast the pandemic

Craig Lipset Former Head of Clinical Innovation Formerly Pfizer


Employ remote digital clinical trials to increase patient diversity and reduce placebo effects in psychiatric studies

  • Learn how Otsuka increased patient diversity and reduced placebo effects while introducing new challenges toward measurement of traditional psychometric assessments in a remote environment
  • Discover how Otsuka employed telemedicine to test virtual engagement of stable patients diagnosed with Major Depressive Disorder using study-in-a-box Bluetooth enabled devices for self-administered collection of vitals, labs and patient reported measures
  • Explore the pragmatic potential of employing telemedicine psychiatric studies in real-world settings

Corey Fowler Director, Global Clinical Development Otsuka


A Reuters News lead interview with Vivek Ramaswamy

Axel Threlfall, Editor-At-Large of Reuters, interviews Vivek Ramaswamy, Chief Executive at Biotechnology company Roivant Sciences, on beginning to give US COVID-19 patients its experimental drug Gimsilumab in a clinical trial on Wednesday.

*Please note: This interview is conducted by Reuters editorial, which operates independently from the Reuters commercial operations. Reuters journalists have the sole right to determine who they interview and the questions they ask, with no regard to sponsorship and in keeping with the Trust Principles of integrity, independence and freedown from bias.

Axel Threlfall Editor-at-Large Reuters

Vivek Ramaswamy Founder and CEO Roivant Sciences


The new clinical ecosystem – who will be disrupted, who will be displaced? Likely pathways to progression

  • Gain market maturity by comprehending today’s spectrum of different approaches – from centralized PIs to virtual and remote networks. An objective perspective on the landscape of approaches and where they’re headed
  • Why new marketplaces and automation could disrupt CROs whilst new data, could disrupt pharma development organizations
    How technology can disrupt the fundamental nature of trial participation for patients and likely pathways to progression

Craig Lipset Former Head of Clinical Innovation Formerly Pfizer

Kyle Flickinger VP Biopharmaceutical solutions Deep Lens

Rohit Nambisan President Lokavant

Jacob LaPorte Co-founder, BIOME Novartis

Jen Horonjeff Founder and CEO Savvy Coop


An interview with Jayne Gershowitz: Build a corporate strategy through greater patient empowerment

Jayne Gershkowitz Chief Patient Advocate Amicus

Paul Simms Chairman eyeforpharma


Augmented Intelligence: When machine learning meets clinical decision making

  • On an almost daily basis, there’s a story around artificial intelligence (AI) or machine learning (ML) leading to a startling breakthrough in healthcare – from algorithms that can reliably diagnose disorders from imaging to identifying new cancer biomarkers from patterns in genetic data. And yet, relatively little is published with respect to real world data (RWD).
  • In this session, Dr. Icten will explore how the explosion of real-world data (RWD), availability of advanced technology coupled with human expertise has created a perfect storm for making data driven decisions that impact the entire product lifecycle.

Zeynep Gozde Icten Director, Data Science Solutions BHE


Use RWE to enhance actual drug use and costs estimation for value-based contract (VBC) design

  • RWD/RWE strategy to improve feasibility of VBC
  • Case study: hands on RWD experience to support VBC design and assessment in chronic and acute disease setting
  • Apply RWD-based decision analysis framework for VBC simulation and assessment

Xin Chen Director, Data Science and Outcomes Research Merck


Fireside chat: Build cross-functional understanding to navigate the diversity of patient entities

  • Why the explosion of patient entities – from expert patients trained in R&D, to advocacy leaders providing HTA input, to individuals living with disease – means it’s time to re-think our policies.
  • How to ensure appropriate company interactions across different patient entities

Amy Nicole Nayar Head, Global Patient relations AbbVie

Durhane Wong-Rieger President Canadian Rare Disease Organisation


Create first-rate patient partnerships: Identify the metrics, improve internal structures and quantify success

  • How to identify concrete goals for patient engagement in regulatory, product development, launch, access and commercial
  • Understand how to improve relationships with patient advocacy groups, holding both parties accountable to goals and metrics
  • How best to create an internal system that allows for easy scaling of patient initiatives and insights

Terri Klein President and CEO MPS Society

Brett Kopelan Executive Director Debra

Jodie Gillon VP, Patient Advocacy & Clinical Affairs Abeona Therapeutics

Melissa Falcone Ex -VP, Patient Services and Reimbursement, Autoimmune and Rare Diseases Formerly Mallinckrodt Pharmaceuticals

Kristin Olson Senior Director, Patient Advocacy Seattle Genetics


An interview with David Epstein: The promise of biotech and early action against COVID-19

David Epstein Executive Partner Flagship Pioneering

Paul Simms Chairman eyeforpharma


Alkermes and Sunovion case studies: Building a blueprint for IDN engagement at scale

  • How Sunovion defined the blueprint for IDN engagement by aligning team capabilities with commercial structure
  • Don’t get trapped in a bubble: how Alkermes created autonomy while staying connected to commercial function strategy
  • Attract, retain and invest in internal talent to build long-lasting, trusted customer partnership

Greg Apostol VP, Key Account Management & Field Reimbursement Alkermes

Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals


Patient group partnerships are the foundation of effective disease awareness strategy

  • Cultivate and nurture patient group outreach to build solid partnerships, based on trust
  • Case Study: How Novo Nordisk collaborated with Magic Foundation to map the patient journey
  • Use insights to support patients to self-advocate for baetter diagnosis and treatment

Nicky Kelepouris US Medical Director-Growth Hormone Novo Nordisk

Mary Andrews CEO The Magic Foundation


Launch the value story: Patient Engagement in research

  • Identify patient needs to guide portfolio strategies
  • Develop product value propositions to optimize coverage and reimbursement
  • Engage patients throughout the lifecycle

Juliette Muszka Global Director, Patient Need and Product Viability, Medical Intelligence & Patient Perspectives Sanofi


Optimizing virtual patient engagement during the COVID-19 pandemic to overcome increased barriers to adherence

Andrea Heslin Smiley President and CEO VMSBiomarketing


Case Study: How Sanofi is optimizing patient data

  • Understand Sanofi’s “usual” methods of collecting patient input into study designs
  • Identify opportunities for improvement in how and when to engage patients
  • Learn from Sanofi’s experience implementing a new patient engagement model

Beth Brooks Patient Network Manager Sanofi


An interview with Sjaak Vink: Why we need a global response to a global outbreak

Sjaak Vink CEO TheSocialMedwork

Paul Simms Chairman eyeforpharma


A whole new (customer engagement) world: Invest for success in 2020

  • What don’t customers want? Understand expectations and the value you can bring
  • Effective techniques for engaging tomorrow’s decision makers and strengthening brand loyalty of patients and HCPs
  • Where to invest resources to strike a successful balance between field and digital marketing channels
  • Incorporate the best and most relevant digital innovations into your customer engagement strategy

Paulo Amaral Global Zoster Multi Channel Marketing Lead GlaxoSmithKline

Frank Doll Chief Marketing Officer Arsenal Therapeutics

Matt Smith Global Lead, Strategy, Digital & Operations Pfizer

Melissa Fellner Global Marketing Director, Respiratory Biologics AstraZeneca

Russell Senyk US Marketing Director Luye


Disney’s best practices for reaching and engaging consumers in the pharma category

HCPs and patients have more choice and control than ever before when it comes to how and where they get their health information. Hear strategies for cutting through the noise and providing the most relevant content to your audience. In this special session, learn how Disney – the biggest brand in media, drives both reach and engagement for pharma marketers. For the first time ever, they will share some proprietary research findings on what works for pharma specifically, as well as best-in-class examples of collaboration with pharma marketers on their platforms.

Flora McKiernan Senior Vice President, Pharmaceutical Disney Advertising Sales


How blockchain is reinventing the pharmaceutical supply chain

  • Hear the latest on the MediLedger initiative, a consortium approach to establish the use of blockchain in the healthcare industry
  • Find out why blockchain technologies having the potential to hugely increase transparency and improve risk management across the supply chain
  • Discover where else blockchain is starting to make a real impact on pharma company workflows and healthcare more broadly

Susanne Somerville CEO Chronicled


Chairman's final words

Paul Simms Chairman eyeforpharma

Workshops (PHARMA ONLY)

Monday, 20th April - 10:00am–11:00am

How will digital health and pharma respond after COVID-19: A roundtable conversation

The COVID-19 pandemic is altering the world that we take for granted, including how we work with each other and interact in a remote environment. The implications to digital health are enormous. In this interactive session, we will take time to explore what we have learned about remote working and how healthcare may be forced to change as a result of stay-at-home restrictions. We will collaboratively explore the implications and potential opportunities for Life Sciences organizations as we look toward a future in which digital health becomes a central component of healthcare delivery.

In this interactive workshop, participants will:

  • Explore how new ways of working have changed our expectations for how we interact with one another in a remote-first environment
  • Learn about how the pandemic is affecting the delivery of healthcare services at a distance and how novel digital approaches are beginning to fill gaps
  • Explore potential ways that our organizations may change and respond as a result of this crisis to embrace digital health

Hosted and facilitated by Medullan

Todd Greenwood Senior Director Client Solutions Medullan

Stephanie Bach Director, UX Medullan

Monday, 20th April - 2:00pm–3:00pm

Stop selling, start educating: how to engage physicians with your content

Physicians don’t want to be sold to. They want a partner in patient care. How do you orient your content to meet your goals, while speaking to doctors at their level?

Learn from Dr. Landy and the team that won the Most Valuable Healthcare/HCP Initiative at the 2019 eyeforpharma awards at this interactive session.

Hosted and facilitated by Figure 1

Dr Joshua Landy Chief Medical Officer Figure1

Tuesday, 21st April - 10:00am–11:00am

Obtaining and Leveraging High-Quality RWD in Immunology and Other Specialty Condition Areas

  • Understand what makes real-world data high quality and fit for purpose
  • Discover opportunities with real-world data for measuring and predicting patient outcomes for research, regulatory and value demonstration purposes including partnering with providers and insurers
  • Explore case examples in Rheumatoid Arthritis, Lupus, Multiple Sclerosis, and other specialty condition areas

Hosted and facilitated by OM1

Richard Gliklich, MD CEO OM1

Tuesday, 21st April - 10:00am–11:00am

Make every interaction matter: Maximizing reach, engagement, and recall in HCP communications in our new reality

Demands on physicians continue to skyrocket. Reduced rep access, burdensome schedules, the proliferation of information channels, and the rapidly increasing volume of medical knowledge already meant opportunities to engage healthcare providers (HCPs) were increasingly fleeting. There has been a constant battle to capture HCP attention and to share data that will be retained, and now the coronavirus pandemic has thrown a dramatic new wrench into HCP engagement initiatives.

How should pharma marketers adjust their approach to meet this new reality? When you get an opportunity to interact with a physician, are you doing everything you can to deliver your message in a way that will be retained? Physicians want education from pharma, and they want it delivered in new ways. You can’t afford to waste the limited opportunities you have to engage HCPs.

Join us for an interactive workshop that will cover how your team can implement:

  • Storytelling and visual communication practices that enhance emotional resonance to make your scientific content more compelling to HCPs, particularly during a crisis
  • Key learning principles that enhance audience engagement and amplify retention
  • Content delivery mechanisms like microlearning and non-personal channels that drive change by providing what physicians want right now
  • Use of repetition to increase recall and shift current beliefs

Hosted and facilitated by MedThink Communications

John Kane VP, Managing Director MedThink Communications

Cassie Stox Senior Director, Media Strategy MedThink Communications

Tuesday, 21st April - 2:00pm–3:00pm

Pivot to the real world: Agile digital strategies pharma marketers use before, during, and after COVID-19

  • Learn from peers how they engage patients during COVID-19
  • Understand how patient-forward digital tactics help biopharma brands amplify their voice
  • See how patient-to-patient connections provide patient and brand value at the same time
  • Discover iterative agile methods that produce impressive results regardless of external circumstances

Hosted and facilitated by Snow Companies

Blake Shewey EVP, Client Service Snow Companies

Laurie Meyers Head of CMG Patient Engagement Genentech

Don Abramo, MBA Sr. Director of Marketing Pharming

Phil Storer SVP Snow Companies

Jon Irvine Creative director Snow Companies

Jessica Proffitt VP, Client Service Snow Companies

Tuesday, 21st April - 2:00pm–3:00pm

What is a “Competitive Insight”? And how do you make it actionable?

Realizing your R&D and Strategic Marketing objectives through Competitive Insights

Imagine you have a $100m marketing budget but don’t know how to spend it. Or, you just spent $100m in marketing but don’t know if your spend was effective.

Competitive Insights are the secret sauce that generate Competitive Advantage from Strategic Intelligence and point to opportunities of impact where it matters most.

Our workshop will offer participants a compressed but unique hands-on experience of generating competitive insights, with a focus on understanding how to make them actionable. C.I. leader Philip Hart and Biotech executive Jack Florio will lead through the session, as will commercial strategist Gloria Kwon, and Deallus U.S. VP Peter Barschdorff. Attend if you are interested in exploring how to leverage strategic intelligence for competitive advantage.

Hosted and facilitated by Deallus

Peter Barschdorff Vice President Deallus

Gloria Kwon Senior Principal Deallus

Philip Hart C.I. Leader Deallus

Jack Florio Biotech Executive Deallus

Wednesday, 22nd April - 10:00am–11:00am

Customer Engagement in Crisis: Leveraging Behavioral Science to Right-Fit Solutions

In the midst of the COVID19 crisis, it is more important than ever for life science leaders to find new ways of authentically engaging and supporting their customers. We can expect that everyone — including patients, physicians and population-based decision makers (PBDMs) — will have new unmet needs and be distracted and even overwhelmed with competing priorities, all while looking for ways to establish their ‘new normal’. The challenge for our industry leaders becomes how to optimize every message and touchpoint for maximal impact. The answer lies in their ability to understand and anticipate their customers’ emerging needs while communicating empathy and delivering relevant experience deserving of customers’ attention. More than ever, life science leaders need to understand the trends driving customer expectations and leverage behavioral science principles underpinning engagement.

In this workshop, you will:

  • Learn how limits to cognitive processing — especially in the current environment — point to opportunities to meet unmet needs
  • Understand how core psychological needs can inspire new ways to gain customer trust
  • Explore the trends driving shifts in patients’, physicians’ and PBDM’s expectations
  • Ideate how your organization can use these new lenses to generate ideas to authentically engage and deliver value

Hosted and facilitated by Syneos Health

Kathleen Starr, PhD Managing Director of Behavioral Science Syneos Health

Drew Beck VP of Insights & Innovation Syneos Health

Khye Tucker Insights & Innovation Strategist Syneos Health

Wednesday, 22nd April - 2:00pm–3:00pm

An Action Plan for Modern Marketing Readiness in a Post-Pandemic World

Pharma has already been facing great changes: no more blockbusters, generics competition is getting more intense, increasingly complex marketing channels, data overload, and very limited access to HCPs. COVID-19 has further complicated the rules.

Let's talk about the impacts of this post-pandemic world and how you can thrive with the pillars of modern marketing. Part evolution and part revolution, modern marketing gives you an actionable roadmap based upon three pillars:

  • Data Driven
  • Customer Experience
  • Applied Technology

Hosted and facilitated by Intouch B2D

David Windhausen EVP of Intouch Group and President of Intouch B2D Intouch B2D

Thursday, 23rd April - 10:00am–11:00am

Evolving the Discussion of Patient Centricity

During the workshop, experts in patient centricity from ZS will share the results from their recent industry survey on patient centricity maturity in the US and EU5. Attendees will break into small group discussion and the session will conclude with real-world case studies in an interactive Q&A format.

Hosted and facilitated by ZS

Sharon Suchotliff Strategy Insights and Planning Manager ZS

Hensley Evans Principal ZS Associates

Victoria Summers Associate Principal ZS Associates

Keri Yale Head, Patient Affairs & Engagement (PA&E) Boehringer Ingelheim Pharmaceuticals

Thursday, 23rd April - 10:00am–11:00am

Formula for effective integrated personalized customer engagement

Learn from Novo Nordisk and Viseven experts how switch to effective digital communication channels to maximize engagement, keep HCPs and Payers up-to-date of disease, product features, and patient support programs, especially when all in-person activities are cancelled.


  1. Market situation analysis due to COVID-19 pandemic
  2. Remote communication: what is inside with infrastructure, channels and content
  3. The impact of remote communication on HCPs time engagement
  4. How to increase Pharma HCP coverage with omnichannel campaigns
  5. Case Study: Building Multichannel Customer Engagement Journeys - engaging customers through marketing automation

Hosted and facilitated by Viseven

Birgitte Dreyer Senior Multichannel Manager Novo Nordisk

Dr. Kenneth Sanchez Chief Officer Viseven USA LLC

Oksana Matviienko Key Account Manager Viseven USA LLC